D. E. Shaw & Co., Inc. Aravive, Inc. Transaction History

D. E. Shaw & Co., Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2019 May 15, 2019	SELL	$3.35 - $8.27 $69,133 - $170,667	-20,637 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.23 - $8.7 $66,657 - $179,541	20,637 New	20,637 $73,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.